SCHEMBL1696396

SCHEMBL1696396

CCCc1cccc(C(=O)NCCCc2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.70
RAB9A P51151 5/20 0.70
POLB P06746 2/20 0.64
KDM4E B2RXH2 1/20 0.64
HPGD P15428 2/20 0.63
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.61
F10 P00742 1/20 0.59
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
EPHX2 P34913 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1696410 0.92 NPC1 (0.72) NPC1RAB9AKDM4EHPGDALDH1A1
SCHEMBL15676736 0.90 NPC1 (0.72) NPC1RAB9APOLBKDM4EHPGD
SCHEMBL1928096 0.87 NPC1 (0.65) NPC1RAB9APOLBKDM4EHPGD
SCHEMBL14233690 0.87 L3MBTL1 (0.67) NPC1RAB9APOLBALDH1A1SMN1; SMN2
SCHEMBL1690505 0.86 NPC1 (0.67) NPC1RAB9APOLBKDM4EHPGD
SCHEMBL29817934 0.84 NPC1 (0.84) NPC1RAB9APOLBKDM4EHPGD
SCHEMBL18773956 0.84 NPC1 (0.84) NPC1RAB9APOLBKDM4EHPGD
SCHEMBL3199651 0.84 SMN1; SMN2 (0.55) NPC1RAB9APOLBHPGDALDH1A1
SCHEMBL1696365 0.84 HDAC6 (0.66) NPC1RAB9APOLBHPGDALDH1A1
SCHEMBL14233914 0.84 KAT6A (0.58) NPC1RAB9APOLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 NPC1 3968/4885RAB9A 818/4885POLB 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.